帕金森病中司来吉兰（丙炔苯丙胺）治疗的临床和药理学问题。
Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson's disease.
作者信息
Stern G M, Lees A J, Hardie R J, Sandler M
出版信息
Acta Neurol Scand Suppl. 1983;95:113-6. doi: 10.1111/j.1600-0404.1983.tb01524.x.
Abstract
The clinical pharmacology concerned in the evolution of deprenyl as an adjuvant in the treatment of Parkinson's disease is briefly reviewed, with an assessment of its therapeutic potential. Experiments to clarify its mode of action are described, indicating that its clinical effects do not depend upon its amphetamine metabolites.
摘要
本文简要回顾了司来吉兰作为帕金森病治疗辅助药物发展过程中的临床药理学，并评估了其治疗潜力。文中描述了旨在阐明其作用方式的实验，结果表明其临床效果并不依赖于其苯丙胺类代谢产物。
Zotero 插件